Next 10 |
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection PR Newswire Tail wind is evaluating inhaled AP-PA02 in non-cystic fib...
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 PR Newswire LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the...
2024-06-27 08:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding high-growth stock opportunities is crucial to constructing a stable and prosperous portfolio. Three outstanding businesses set up for remarkable development in 2024 are highlighted here...
2024-05-07 18:29:10 ET More on Armata Pharmaceuticals Armata Pharmaceuticals reports Q4 results Armata enters $35M credit agreement with Innoviva Seeking Alpha’s Quant Rating on Armata Pharmaceuticals Historical earnings data for Armata Pharmaceuticals...
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update PR Newswire LOS ANGELES , May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high...
2024-03-21 17:19:19 ET More on Armata Pharmaceuticals Armata enters $35M credit agreement with Innoviva Seeking Alpha’s Quant Rating on Armata Pharmaceuticals Historical earnings data for Armata Pharmaceuticals Financial information for Armata Pharmace...
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update PR Newswire LOS ANGELES , March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology com...
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva PR Newswire Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES , March 4, 20...
Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit PR Newswire LOS ANGELES , Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on...
2023-11-14 17:11:39 ET More on Armata Pharmaceuticals Seeking Alpha’s Quant Rating on Armata Pharmaceuticals Historical earnings data for Armata Pharmaceuticals Financial information for Armata Pharmaceuticals For further details see: Armata Pharma...
News, Short Squeeze, Breakout and More Instantly...
Armata Pharmaceuticals Inc. Company Name:
ARMP Stock Symbol:
NYSE Market:
Armata Pharmaceuticals Inc. Website:
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection PR Newswire Tail wind is evaluating inhaled AP-PA02 in non-cystic fib...
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024 PR Newswire LOS ANGELES , July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the...